Cholinesterase inhibitors and memantine for treatment of dementia
Cholinesterase inhibitors and memantine may be offered to people with dementia in non-specialist health settings. Non-specialists need to be trained and supervised to ensure competence in diagnosis and monitoring.
The use of cholinesterase inhibitors should be focused upon those with mild to moderate Alzheimer's disease, where the majority of evidence is available.
Memantine may be considered for those with moderate to severe Alzheimer’s disease and vascular dementia. Memantine should not be prescribed for Lewy Body dementia.
Strength of recommendation: CONDITIONAL
Quality of evidence: VERY LOW